Genelux Corporation Common Stock (GNLX)
Healthcare
Biotechnology
3.00 $
+1.4%
vs. previous close
Closing price · As of: 3. Aug 2026
Genelux Corporation Common Stock (GNLX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -25 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| -7.2 | -7.2 | -6.6 | -3.6 | -20 | -21 | -25 | |
| 0.5 | 0.7 | 0.9 | 1.0 | 1.0 | 0.9 | 0.2 | |
| – | 5.3 | 4.3 | 2.4 | 5.2 | 6.1 | 5.9 | |
| 3.8 | 5.3 | 4.6 | 2.1 | – | – | – | |
| 0.1 | 0.4 | 4.1 | -1.7 | -3.3 | 0.8 | -1.0 | |
| 1.8 | 0.0 | 0.0 | 0.0 | 1.0 | 0.4 | 1.1 | |
| -1.8 | 0.0 | 0.0 | 0.0 | -15 | -8.1 | 12 | |
| 1.5 | 9.2 | -0.6 | 1.0 | 0.2 | 0.0 | – | |
| 7.9 | 18 | -0.3 | -0.5 | 44 | 29 | 9.9 | |
| -1.1 | 11 | -6.9 | -4.1 | 9.0 | -0.9 | -3.2 | |
| -9.0 | -7.2 | -6.6 | -3.6 | -21 | -22 | -26 |
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.